By the way ignore all the jolly short morons...just hit the ignore button. They hate being ignored.
The IBB is a Biotech MF. Since the Fed made a broad generalization about the Biotech sector, then really we are talking about the IBB. Its down and there is no sign of reverse at this time. ACAD will tend to be more volatile than the IBB, i.ei higher Beta, but there is a correlation. ACAD tends to follow the IBB, but with a higher Beta. ie more extreme moves. This may help identify a reverse.
ez all the CPA's I have ever known are really top of their game. One was the CFO for a company Coffee & Tea Leaf (? name), really smart people. They are not just accountants. Its not an easy degree. A BA degree in Business is way easier. An MBA is a great degree too.
With a Billion dollar drug on deck and a NDA pending this stock is going to make a major move higher in no time. Note she gives not one detail about which stocks, what % of the biotechs is over valued etc. This is a generalization and I think there are some Biotechs over valued, but ACAD is not one of them.
"Valuation metrics in some sectors do appear substantially stretched—particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year," said remarks in the full policy report accompanying Yellen's testimony.
So did the entire biotech sector hire cfo's today ...come on, tell your brain cells to hold hands.
You are a real dimwit you know that...look at the biotech sector dude...MNKD MannKind Corp. -0.09 -0.90% 9.88 242.16M 3.8 11.48 - - - - 10.02 9.97 0.046 -
GILD Gilead Sciences Inc. -0.34 -0.38% 89.51 1.53B 55.96 90.74 - - - - 83.0456 89.85 8.736 -
CLDX Celldex Therapeutics, Inc. -0.53 -3.68% 13.87 89.11M 10.76 38.84 - - - - 15.91 14.40 3.27 -
MYGN Myriad Genetics Inc. -1.46 -3.61% 38.95 74.50M 20.02 42.5 - - - - 36.29 40.41 9.69 -
ACAD ACADIA Pharmaceuticals Inc. -0.59 -2.67% 21.50 73.29M 15.64 32 - - - - 22.35 22.09 3.7 -
IBB iShares Nasdaq Biotechnology -3.85 -1.49% 254.25 0.00 187.05 275.4 - - - - 251.11 258.10 0 -
SLV iShares Silver Trust -0.18 -0.92% 19.92 - 17.91 23.84 - - - - 19.33 20.10 - -
CPHD Cepheid -1.19 -2.38% 48.76 68.67M 30.95 55.89 - - - - 46.77 49.95 5.07 -
VTI Vanguard Total Stock Market ETF -0.24 -0.23% 101.99 - 84.6 103 - - - - 101.18 102.23 - 1.08
QQQ PowerShares QQQ -0.32 -0.33% 95.52 0.00 74.2 96.13 - - - - 93.11 95.84 0 -
GLD SPDR Gold Shares -0.91 -0.72% 124.81 - 114.46 137.55 - - - - 124.26 125.72 - -
Believe me even if the Biotech was 50% lower they would still say it is over valued. They really want dirt cheap drug costs.
When I worked for one of the biggest HMO's in the west coast who had their own pharmacy, it was hammered home at EVERY MEETING...the biggest expense...was not the hospital cost....not malpractice insurance...but the cost of drugs, especially new brand name drugs. They bombarded us with graphs and charts about generics vs brand name meds over and over again. They sent out individual stat sheets comparing your own drug prescriptions use compared to all your other doctors so you could see if you were ordering more brand name drugs than the average doctor. If you you were an outlier you had a month or so to get back in line...if you didn't, you had a sit down with the Chief of your Dept. Ouch! If that didn't get your attention then how about a 10% cut in pay if you were on contrat or "full time " doc. Of course if you were just a per diem...they would just not give you hours, basically they fired you. So get the picture. So what does this have to do with biotechs and the fed....MEDICARE. Do you understand what is happening right now....Millions upon millions of baby boomers are getting Medicare ...we paid for it via SS and now at 65 its an entitlement, although the government is still sticking it to us with the extra fees if you "make too much " ie Obama Care. It is still eating up a humongous amount of government funds and the one thing they can't get a handle on is drug costs.
This guy is a great fit...ton's of experience in Biotech. CPA is a an excellent degree for a CFO, and a JD from Vanderbilt to boot. He will work out just fine.
Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry. He most recently served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., which he joined in 2013. He led core business and finance functions there and was instrumental in developing and implementing a new corporate strategy with a multi-program portfolio. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013, where he oversaw business functions, including finance, commercial planning, and corporate development, and played a critical role in building and growing the company. Prior to joining Ardea, Mr. Davis served in numerous executive roles at Neurogen Corporation from 1994 to 2010, including Chief Financial Officer, Chief Operating Officer, and Chief Executive Officer, completing multiple collaborations and product acquisitions with global pharmaceutical companies. Mr. Davis currently serves on the Board of Directors of Heron Therapeutics and Synageva BioPharma Corp.
Earlier in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
I agree the $22..50 seemed really weak . I was very surprised it cracked so easily-Perhaps because the stock opened so weak. $hit happens I guess. But in general, the numbers are ...more like a guide with each number giving its relative strength. So chill and stop being such a numb skull and shut your pie hole, use it or ignore it, your choice.
Your relative has severe PDP and is an in-patient in a costly SNF- Then PIMA gets released and it stabilizes your relative enough to be discharged home from the SNF. Wow how cool is that.
The European Union has about 1.6 Million Parkinson's Disease patients. So 640,000 will need treatment for PDP at some point.